Double-blind, randomized, exploratory, multicenter clinical study to evaluate the efficacy and safety of D--Beta hydroxybutyrate in depressed patients

未提供0 个研究点目标入组 90 人开始时间: 2024年3月1日最近更新: 2025年6月2日

适应症

试验速览

暂无简介。

•20 years old above male or female
•Patient who have a diagnosis of depression based on the Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (DSM-5) at the start of screening visit and are attending outpatient clinic
•Patient must administer less than 2 antidepressant with optimum dose within 28 days of enrollment, and must be stable of depression symptom and meet the depression symptom severity (MADRS total score greater than or equal to 22) at the enrollment.
•If the patient has received sleeping or anxiolytic medications (including those taken by tonics) in the 14 days prior to the start of the double-blind period, the dosage and administration must not have been changed.
•Patient who have a regular diet
•Patient must be medically stable on the basis of assessment and observation performed in the screening visit
•Patient give informed consent

•Patient with moderate or higher infection
•Patient with is drug addic
•Patients with imminent suicidal thoughts or a history of suicide attempts between the date consent was obtained and the administration of the study drug.
•Patients receiving anti-inflammatory drugs, immunosuppressants, SGLT2 inhibitors, or steroids. However, the local use of anti-inflammatory drugs, immunosuppressants, or steroids, as well as the as-needed use of anti-inflammatory drugs, is permitted.
•Patient with malignancy
•Patient with severe organ disorder (cardiovascular disturbanc
•Patient with diabetes
•Patient with dementia or sychiatric disease other than depression
•Patient who have a carbohydrate-restricted diet
•Patients requiring potassium intake restriction
•Subject who do not agree to refrain from excessive exercise during the study drug administration
•Patient who are preg nant or nursing or who desire to become pregnant during the study period. Patients who or whose partners are unwilling to agree to practice appropriate contraception during the study period
•Patient who had other study drug
•Patients deemed by the principal investigator to be ineligible for inclusion.

Change in MADRS Total Score as Measured by the Change From Baseline to the end of the 8-Week.

未报告次要终点

发起方

未提供